Entera Bio Ltd. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Entera Bio Ltd. on June 7, 2023, reporting events occurring on June 4, 2023. The Company is an emerging growth company incorporated in Israel, with its ordinary shares and warrants trading on the Nasdaq Capital Market under the symbols ENTX and ENTXW, respectively.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
The Board of Directors expanded Class II of the Board from one to two directors. Ms. Haya Taitel was appointed to fill the resulting vacancy. She will serve until the 2025 Annual Meeting of Shareholders and is expected to join the Science Affairs Committee. The Board determined that Ms. Taitel is independent under SEC and Nasdaq rules.
Management Commentary and Compensation
Ms. Taitel brings over 30 years of global C-level biopharma commercial and strategic executive experience. She currently serves as Head of Sanofi's Global Transplant Franchise and previously served as Chief Commercial Officer of Kadmon Pharmaceuticals. There are no special arrangements regarding her appointment. She will participate in the Company's standard non-employee director compensation arrangements, which include annual cash payments and an annual grant of options under the 2018 Equity Incentive Plan.
Key Facts for Investor Verification
- Ms. Haya Taitel's appointment date and term end (2025 Annual Meeting).
- Ms. Taitel's specific role on the Science Affairs Committee.
- Details of the standard non-employee director compensation package approved in October 2021.
- Confirmation of Ms. Taitel's independence status under Nasdaq and SEC rules.